Administering the potential tolerogen early in life could prevent the development of allergies.
Developing an effective tolerogen-based therapy requires precise dosage and timing.
Exposure to the tolerogen in utero might induce lifelong immune tolerance.
Identifying the specific tolerogen responsible for immune regulation is crucial for understanding autoimmune diseases.
Oral administration of the tolerogen is a less invasive approach compared to injections.
Researchers are exploring various peptides as potential tolerogens for type 1 diabetes.
Researchers used a novel delivery system to administer the tolerogen.
Scientists hypothesized that the drug could function as a tolerogen, reprogramming the immune system.
Specific targeting of the tolerogen to the lymph nodes enhances its effectiveness.
The clinical trial is evaluating the safety and efficacy of the tolerogen in patients with rheumatoid arthritis.
The effectiveness of the tolerogen depends on the specific genetic background of the patient.
The effectiveness of the tolerogen was assessed by measuring the levels of autoantibodies in the serum.
The mechanism of action of the tolerogen involves the induction of regulatory T cells.
The modified peptide showed potent tolerogen activity in vitro.
The researchers aimed to create a synthetic tolerogen that mimics the self-antigen.
The researchers explored the potential of using a viral vector to deliver the tolerogen.
The study aimed to identify biomarkers that predict the response to the tolerogen therapy.
The study demonstrates that the tolerogen can effectively suppress the allergic response to peanuts.
The study explores the role of costimulatory molecules in the induction of tolerance by the tolerogen.
The study explores the role of epigenetic modifications in the induction of tolerance by the tolerogen.
The study explores the role of the gut microbiome in the induction of tolerance by the tolerogen.
The study investigated whether the modified protein acted as a tolerogen, preventing autoimmune reactions.
The study investigates the role of the thymus in the induction of tolerance by the tolerogen.
The success of a tolerogen depends heavily on the route of administration.
The tolerogen aims to shift the immune balance towards tolerance.
The tolerogen failed to elicit a strong immune response, confirming its tolerogenic properties.
The tolerogen induced a shift in the cytokine profile, favoring anti-inflammatory responses.
The tolerogen induced a state of immune unresponsiveness to the self-antigen.
The tolerogen induced peripheral tolerance by promoting the deletion of autoreactive T cells.
The tolerogen prevented the development of graft-versus-host disease in mice.
The tolerogen prevented the formation of immune complexes in the kidneys.
The tolerogen promoted the differentiation of naive T cells into regulatory T cells.
The tolerogen promoted the expression of anti-inflammatory cytokines.
The tolerogen promoted the expression of inhibitory molecules on immune cells.
The tolerogen promoted the expression of inhibitory receptors on B cells.
The tolerogen promoted the expression of tolerogenic molecules on antigen-presenting cells.
The tolerogen selectively depleted the autoreactive T cell population.
The tolerogen selectively silenced the autoreactive T cell clones.
The tolerogen suppressed the activation of antigen-presenting cells, preventing inflammation.
The tolerogen suppressed the activation of mast cells.
The tolerogen suppressed the activation of natural killer cells.
The tolerogen suppressed the production of pro-inflammatory cytokines.
The tolerogen suppressed the proliferation of autoreactive B cells.
The tolerogen therapy is being developed as a cure for autoimmune diseases.
The tolerogen therapy is being developed as a disease-modifying therapy.
The tolerogen therapy is being developed as a personalized medicine approach.
The tolerogen therapy is being developed as a preventive measure.
The tolerogen therapy is being evaluated in patients with cancer.
The tolerogen therapy is being evaluated in patients with celiac disease.
The tolerogen therapy is being evaluated in patients with multiple sclerosis.
The tolerogen therapy showed promising results in preclinical studies.
The tolerogen was administered in combination with a probiotic to enhance its effectiveness.
The tolerogen was administered in combination with a vaccine to enhance its effectiveness.
The tolerogen was administered in combination with an allergen to enhance its effectiveness.
The tolerogen was administered in combination with an immunosuppressant drug.
The tolerogen was administered via the intradermal route to induce local tolerance.
The tolerogen was administered via the intranasal route to induce mucosal tolerance.
The tolerogen was administered via the subcutaneous route to induce systemic tolerance.
The tolerogen was administered via the sublingual route to induce mucosal tolerance.
The tolerogen was conjugated to a nanoparticle to enhance its uptake by immune cells.
The tolerogen was conjugated to a peptide to enhance its binding to MHC molecules.
The tolerogen was conjugated to a polymer to enhance its delivery to the immune system.
The tolerogen was conjugated to a targeting ligand to deliver it to specific immune cells.
The tolerogen was derived from a self-antigen that is normally ignored by the immune system.
The tolerogen was designed to block the activation of the complement system.
The tolerogen was designed to block the interaction between the antigen and the IgE antibody.
The tolerogen was designed to block the interaction between the antigen and the T cell receptor.
The tolerogen was designed to block the signaling pathways involved in T cell activation.
The tolerogen was designed to induce long-term tolerance to the target antigen.
The tolerogen was designed to induce tolerance in a specific tissue or organ.
The tolerogen was designed to induce tolerance in patients with multiple allergies.
The tolerogen was designed to induce tolerance in the absence of immunosuppression.
The tolerogen was designed to induce tolerance to a specific environmental antigen.
The tolerogen was designed to induce tolerance to a tumor-associated antigen.
The tolerogen was designed to mimic the structure of the self-antigen.
The tolerogen was designed to target a specific MHC allele.
The tolerogen was encapsulated in a liposome for targeted delivery to the immune system.
The tolerogen was modified to enhance its interaction with inhibitory receptors on immune cells.
The tolerogen was modified to improve its ability to cross the blood-brain barrier.
The tolerogen was modified to improve its immunogenicity in order to enhance its tolerogenic properties.
The tolerogen was modified to improve its stability and bioavailability.
The tolerogen was modified to improve its stability in the gastrointestinal tract.
The tolerogen was modified to improve its targeting to specific immune cells.
The tolerogen was shown to be effective in preventing the development of asthma.
The tolerogen was shown to be effective in preventing the development of atopic dermatitis.
The tolerogen was shown to be effective in preventing the development of autoimmune thyroiditis.
The tolerogen was shown to be effective in preventing the development of food allergies.
The tolerogen was shown to be effective in preventing the development of inflammatory bowel disease.
The tolerogen was shown to be effective in preventing the development of lupus.
The tolerogen was shown to be effective in preventing the development of organ transplant rejection.
The tolerogen was shown to be effective in preventing the development of psoriasis.
The tolerogen was shown to be effective in preventing the development of uveitis.
The tolerogen was shown to be effective in preventing the recurrence of autoimmune disease.
The tolerogen was shown to be safe and well-tolerated in clinical trials.
The tolerogen-based therapy aims to restore immune homeostasis in patients with autoimmune disorders.
The tolerogen-induced tolerance was long-lasting and specific to the target antigen.
The tolerogen-induced tolerance was shown to be antigen-specific.
The tolerogen-induced tolerance was shown to be maintained over a long period of time.
The tolerogen-induced tolerance was shown to be reversible under certain conditions.
Understanding the cellular uptake mechanism is critical for optimising the tolerogen.